Author: Williamson, E. D.
Title: Vaccines for emerging pathogens: from research to the clinic Document date: 2019_4_16
ID: jri02z0a_2
Snippet: Understanding the interaction of the host with a viral pathogen to expedite vaccine development is a theme taken up in the review contributed by Sharpe et al. [2] . Specifically, they address the targeting of the human leucocyte antigen (HLA)-E molecule, a major histocompatibility complex (MHC)1b molecule, by viral vectors to induce non-classical CD8 + T cell immunity and to inhibit natural killer (NK) cell activity. However, the authors acknowle.....
Document: Understanding the interaction of the host with a viral pathogen to expedite vaccine development is a theme taken up in the review contributed by Sharpe et al. [2] . Specifically, they address the targeting of the human leucocyte antigen (HLA)-E molecule, a major histocompatibility complex (MHC)1b molecule, by viral vectors to induce non-classical CD8 + T cell immunity and to inhibit natural killer (NK) cell activity. However, the authors acknowledge that there remain some questions of safety with this HLA-E targeting approach to vaccination; for example, the existence of self-peptides which are able to up-regulate HLA-E activity. The preclinical data, for
Search related documents:
Co phrase search for related documents- host interaction and natural killer: 1, 2
- major histocompatibility complex and molecule major histocompatibility complex: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
- major histocompatibility complex and natural killer: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30
- major histocompatibility complex and natural killer NK cell activity: 1
- major histocompatibility complex and NK cell activity: 1, 2
- major histocompatibility complex and self peptide: 1, 2
- major histocompatibility complex and vaccine development: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30
- major histocompatibility complex and viral pathogen: 1
- major histocompatibility complex and viral vector: 1
- molecule major histocompatibility complex and natural killer: 1, 2
- natural killer and NK cell activity: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30
- natural killer and vaccine development: 1, 2, 3, 4, 5, 6, 7, 8, 9
- natural killer and viral pathogen: 1, 2, 3, 4, 5
- natural killer and viral vector: 1, 2, 3
- natural killer NK cell activity and NK cell activity: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
- self peptide and vaccine development: 1, 2, 3, 4, 5
- self peptide and viral pathogen: 1
- vaccine development and viral pathogen: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20
- vaccine development and viral vector: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56
Co phrase search for related documents, hyperlinks ordered by date